Donepezil did not reduce the rate of institutionalisation or disability in people with mild to moderate Alzheimer's disease.
نویسنده
چکیده
MAIN RESULTS At 60 weeks, there were no significant differences between donepezil and placebo in institutionalisation rates or progression to disability in people with mild to moderate Alzheimer’s disease (see http:// www.ebmentalhealth.com/supplemental for table). There were no significant differences in institutionalisation rates between the 10 mg and 5 mg donepezil groups (10 mg v 5 mg: 37 v 44, p=0.7).
منابع مشابه
Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.
BACKGROUND Cholinesterase inhibitors produce small improvements in cognitive and global assessments in Alzheimer's disease. We aimed to determine whether donepezil produces worthwhile improvements in disability, dependency, behavioural and psychological symptoms, carers' psychological wellbeing, or delay in institutionalisation. If so, which patients benefit, from what dose, and for how long? ...
متن کاملReview: donepezil improves cognitive and global function in people with mild to moderate Alzheimer's disease.
Study selection and analysis: Eligible studies were randomised controlled trials comparing donepezil versus placebo in people with mild to moderate Alzheimer’s disease (MMSE criteria). Trials were undertaken and completed by 20 December 1999. Exclusions: not stated. Data were extracted for each individual study on the efficacy and safety of donepezil. Meta-analysis was carried out using fixed a...
متن کاملEffects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study.
AZD3480 is a selective agonist of the central α4β2 and α2β2 neuronal nicotinic cholinergic receptors (NNRs). Its effects on cognition were investigated in 567 patients with mild-to-moderate Alzheimer's disease (AD) (Mini Mental State Examination [MMSE] 12-26). Mean baseline MMSE was 21 (SD ± 3.7), with 61% of patients having mild disease (MMSE 21-26). Mean age was 74 (range 58-85) years. Patien...
متن کاملThe recent development in synthesis and pharmacological evaluation of small molecule to treat Alzheimer's diseases: A review
Alzheimer's disease is a neurological disorder in which the death of brain cells causes memory loss and cognitive decline. A neurodegenerative type of dementia, the disease starts mild and gets progressively worse. Like all types of dementia, Alzheimer's is caused by brain cell death. The most common presentation marking Alzheimer's dementia is where symptoms of memory loss are the most promine...
متن کاملThe recent development in synthesis and pharmacological evaluation of small molecule to treat Alzheimer's diseases: A review
Alzheimer's disease is a neurological disorder in which the death of brain cells causes memory loss and cognitive decline. A neurodegenerative type of dementia, the disease starts mild and gets progressively worse. Like all types of dementia, Alzheimer's is caused by brain cell death. The most common presentation marking Alzheimer's dementia is where symptoms of memory loss are the most promine...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Evidence-based mental health
دوره 7 4 شماره
صفحات -
تاریخ انتشار 2004